Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of DCVAC/PCa plus docetaxel/prednisone versus placebo plus docetaxel/prednisone in metastatic castration-resistant prostate cancer
NL-OMON46876Phase 3Active, not recruiting
- Sponsor
- SOTIO Biotech
- Start
- Nov 2014
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing DCVAC/PCa + standard of care chemotherapy with Placebo + standard of care chemotherapy (2 arms). Primary endpoint: Overall survival. Started Nov 2014; status: active, not recruiting.
02
Drugs
DCvac
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON46876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46876.